FDA approves wider marketing for Enbrel

06/2/2005 | MSN Money

Amgen and Wyeth Pharmaceuticals reported the FDA approved expanded marketing for Enbrel to treat arthritis associated with psoriasis. The decision allows the companies to market Enbrel for improvement of physical function in patients with psoriatic arthritis in addition to the previously approved treatment for signs and conditions of the disease.

View Full Article in:

MSN Money

Published in Brief:

SmartBrief Job Listings for Health Care